The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.
Akhil Chopra
No relevant relationships to disclose
Stefan Gluck
No relevant relationships to disclose
Alberto J. Montero
No relevant relationships to disclose
Kiran Kumar Venkata Raja Avancha
No relevant relationships to disclose
Gilberto Lopes
No relevant relationships to disclose